TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Rectal Tumor Margin Using Confocal Endomicroscopy and Comparison to Histopathology

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient, male or female over 18 years old~* Patient with rectal adenocarcinoma :~  * stage T1 or T2, N0 (one single evaluation, during resection)~ * stage N+ or T3 (pre- and post-radiochemotherapy evaluations)~* Absence of contra-indication to rectoscopy conduct~* Patient able to understand the study and to provide written informed consent~* Patient registered with the French social security regime~Non-inclusion criteria:~* Absence of written informed consent~* Patient with known or suspected allergy to fluorescein~* Patient with history of reaction jeopardizing the vital prognosis during angiography~* Patient with history of multiple or serious allergic reaction to drugs~* Patient presenting, in the investigator's judgment, a condition or disease preventing their participation to study procedures~* Patient pregnant or breast-feeding~* Patient within exclusion period from other clinical trial~* Patient having forfeited their freedom of an administrative or legal obligation~* Patient being under guardianship

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Validation of CPR for Manipulation for Neck Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Primary complaint of mechanical neck pain with or without unilateral upper extremity symptoms (mechanical neck pain is defined as neck pain/ symptoms that are altered/ affected by activity, movement and posture)~* NDI score at least 10 points out of 50.~Exclusion Criteria:~* Red flags noted in the patient's Neck Medical Screening Questionnaire (i.e. tumor, fracture, metabolic diseases, Rheumatoid Arthritis, osteoporosis, prolonged history of steroid use, etc.)~* History of whiplash injury within the past six weeks~* Diagnosis of cervical spinal stenosis or bilateral upper extremity symptoms~* Evidence of central nervous system involvement, to include hyperreflexia, sensory disturbances in the hand, intrinsic muscle wasting of the hands, unsteadiness during walking, nystagmus, loss of visual acuity, impaired sensation of the face, altered taste, the presence of pathological reflexes (i.e. positive Hoffman's and/or Babinski reflexes), etc.~* Two or more positive neurologic signs consistent with nerve root compression, including any two of the following: a. Muscle weakness involving a major muscle group of the upper extremity b. Diminished upper extremity muscle stretch reflex (biceps brachii, Brachioradialis, or triceps reflex) c. Diminished or absent sensation to pinprick in any upper extremity dermatome~* Prior surgery to the neck or thoracic spine~* Pending legal action regarding their neck pain~* Insufficient English language skills to complete all questionnaires~* Inability to comply with treatment and follow-up schedule

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Manipulation (Type: EXPERIMENTAL): Patients will receive cervical manipulation on 2 visits and then a further 3 visits of therapeutic exercises
- Exercise (Type: OTHER): Patients will receive 5 visits of therapeutic exercises

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the MANOS Carpal Tunnel Release System in Patients With Carpal Tunnel Syndrome

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient is scheduled to undergo carpal tunnel release surgery.~* Patient has chronic Carpal Tunnel Syndrome with persistent symptoms despite non-operative treatment, or refusal of non-operative treatment, with one or more of the following: splinting, NSAIDs or corticosteroid injections.~* Carpal Tunnel Syndrome must be confirmed by positive results of Electromyography (EMG) and Nerve Conduction Velocity (NCV) tests.~* Patient is a male or non-pregnant, non-lactating female.~* Patient is 18-75 years of age, inclusive.~* Female patients of child-bearing potential, including those who have had a tubal ligation, but excluding those who have not experienced a menstrual period for at least two years, must have a negative urine pregnancy test at Screening.~* Patient must voluntarily provide written, informed consent.~Exclusion Criteria:~* Patient has a prior or current musculoskeletal or neurologic condition that limits strength, motion, or sensation in the affected hand.~* Patient has a medical condition that precludes the use of anesthetic required for surgery.~* Patient has an ipsilateral injury or other conditions affecting hand function.~* Patient has acute CTS resulting from an injury (e.g., fracture).~* Patient has had previous CTR surgery on the affected hand.~* Patient has psychiatric history, head injury or any other condition which, in the Investigator's opinion, would prevent patient from complying with post-operative hand therapy or follow-up visits.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced Stage IIIB or IV non-small-cell lung cancer (NSCLC)~* Eastern Oncology Cooperative Group (ECOG) Performance Status 0 or 1~* Prior therapy defined as 1 prior systemic therapy for advanced disease~* Documented disease progression during or following most first line therapy for advanced disease~* Adequate hematologic, hepatic, renal function~Exclusion Criteria:~* Epidermal growth factor receptor (EGFR) mutations~* Anaplastic lymphoma kinase (ALK) translocations~* Predominantly squamous, adenosquamous or unclear histologic type~* Active or untreated central nervous system (CNS) metastases~* Active malignancies other than NSCLC within the last 5 years with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin~* Serious cardiac illness or medical conditions~* Pregnant or lactating women~* Uncontrolled intercurrent illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ganetespib and Docetaxel (Type: EXPERIMENTAL): Ganetespib (150 mg/m\^2) and docetaxel (75 mg/m\^2) were administered as separate 1-hour IV infusions on Day 1 of each 3-week treatment cycle. Administration of ganetespib preceded the administration of docetaxel. Ganetespib was administered again on Day 15 of each cycle.
- Docetaxel (Type: ACTIVE_COMPARATOR): Docetaxel (75 mg/m\^2) was administered on Day 1 of a 3-week treatment cycle by 1-hour IV infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The Incidence of Glistenings in the 2017 Intraocular Lenses Made by Alcon and Abbott Medical Optics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients consulting 5 surgeons for cataract surgery in the surgeon's primary offices~* Patients aged 18 years or older~* Patients who signed the consent form~Exclusion Criteria:~* Individuals who cannot understand English in either written or verbal form and do not have language assistance available (e.g. from family members, friends)~* Patients with co-existing condition of corneal disease~* Patients with co-existing condition of uveitis~* Patients with co-existing condition of optic nerve disease~* Patients with co-existing condition of macular disease~* Patients with co-existing condition of diabetes~* Patients with co-existing condition of severe glaucoma (i.e. C/D ratio \>=0.9 AND the patient is on glaucoma treatment)~* Patients with prior refractive surgery~* Patients with complications of cataract surgery occurred during or after surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alcon lens group (Type: EXPERIMENTAL): Alcon 1 piece SA60AT lens
- AMO lens group (Type: ACTIVE_COMPARATOR): AMO 1 piece Sensar AABOO lens

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Incomplete upper motor neuron lesion~* Detrusor overactivity~* Two leaks or two notices of leaks per day~* Mean functional bladder capacity (volume voided per episode) of ≥100 ml~Exclusion Criteria:~* Complete spinal lesion or complete bilateral lesion of sacral / pudendal nerves.~* Degenerative disease of the central nervous system

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ON / OFF (Type: OTHER): Stimulation ON for 4 weeks, followed by stimulation OFF for 4 weeks.
- OFF / ON (Type: OTHER): Stimulation OFF for 4 weeks, followed by stimulation ON for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Flexor Tenosynovectomy to Treat Recurrent Carpal Tunnel Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (\> 18 years)~* Patient of The Plastic Surgery Group/Hayes Hand Center~* Previous diagnosis of Carpal Tunnel Syndrome~* Diagnosis of Recurrent Carpal Tunnel Syndrome~* Underwent primary carpal tunnel release~* Undergoing isolated flexor tenosynovectomy as secondary procedure~Exclusion Criteria:~* Had incomplete primary release of transverse carpal ligament~* Had documented neuroma upon re-exploration~* Had other soft tissue tumor within carpal tunnel or providing reasonable contribution to neurologic symptoms~* Experienced fracture or other traumatic injury to wrist after primary carpal tunnel release~* Diagnosis of osteomyelitis, infectious tenosynovitis or other infectious etiology to area of interest after primary procedure~* Diagnosis of rheumatoid arthritis, psoriatic arthritis, or other inflammatory arthropathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Flexor tenosynovectomy surgery (Type: None): Adult patients who will be undergoing flexor tenosynovectomy for the treatment of recurrent carpal tunnel syndrome and who have already undergone primary carpal tunnel release surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: PADN to Treat Severe Obstructive Sleep Apnea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Apnea hypopnea index more than 30, not tolerated or refused continuous positive airway pressure;~Exclusion Criteria:~* Acute coronary syndrome;~* Pregnant;~* Expected life less than 12 months;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Sham procedure (Type: SHAM_COMPARATOR): Patients in the sham group will take sham procedure like PADN.
- Pulmonary Arterial Denervation (Type: EXPERIMENTAL): Contrast pulmonary artery （PA) angiography was performed to localize the pulmonary artery bifurcation level and calculate the PA diameter.Once the anatomy was deemed acceptable, the radiofrequency ablation catheter was introduced into the distal bifurcation area of the main PA.This was then maneuvered within the PA to allow energy delivery to ensure that the electrodes were tightly in contact with the endovascular surface. About two to three ablations at 1-15 W for 240 seconds each point were performed in the distal bifurcation area of the main PA.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Ability of NIRS to Predict Brain Injury in Hypoxic Ischemic Encephalopathy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Infants with diagnosis at birth of HIE~Exclusion Criteria:~* none

- Gender: ALL
- Minimum Age: 1 Minute
- Maximum Age: 2 Years
- Healthy Volunteers: f

Study Arms:
- HIE (Type: None): Infants with a diagnosis of HIE

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Self-management of Type 1 Diabetes Under Functional Insulin Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 diabetes from at least 1 year~* Age from 18 to 70 (70 not included)~* Basal-bolus multiple-dily insulin injections or insulin pump (CSII)~* Informed consent~* Affiliated or benefit from an insurance regimen~Exclusion Criteria:~* Type 2 diabetes~* Unable to make mathematic calculation~* Pregnancy, breast-feeding or absence of effective contraception~* Psychiatric and/or cognitive status uncompatible with study~* Eating disorders~* Law protected person, vulnerable person

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Education to functional insulin therapy immediately (Type: EXPERIMENTAL): Immediately after inclusion, patients will follow a functional insulin therapy training course during 2.5 days.
- No education to functional insulin therapy immediately (Type: OTHER): After inclusion in the study, patients go on usual diabetes management. At the end of study, they will receive education to functional insulin therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Hypertonic Saline and Terlipressin for Sepsis-associated Hypotension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Criteria of SIRS: at least 2 of 4:~  * Temperature \> 38 °c or \< 36 ° C~ * More than 90 bpm heart rate~ * Respiratory rate more than 20rpm or PaCO2 less than 32 mm Hg or patient in mechanical ventilation~ * Less than 4000/ mm³ or more than 12000/mm³, or more than 10% leukocyte bands (immature)~* Septic source known demonstrated (or at least of high probability) and controlled (if it is controllable)~* Hematocrit 25% or higher and/or hemoglobin 8 g/dL or higher. If necessary, transfuse RBCs to meet this criteria~* MAP less than 70 mm Hg. Note there is no requirement for adequate preload evidence~Exclusion Criteria:~* Hypernatremia at base-line of 155 mEq/L or greater Hyponatremia at base-line less than 130mEq / L~* Prior endocrine disease affecting to the adrenal-pituitary axis.~* Intracranial Hypertension, brain tumor, seizures, head trauma~* Coronary Artery Disease active over the past year; or evidence of myocardium at risk by exercise stress test, pharmacological or positive gammagraphy last year without intervention~* Pregnancy~* Liver disease Child C, End-Stage-Renal-Disease~* Under the age of 18~* Patients with order do not resuscitate or with minimal chances to survive

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Hypertonic Saline and Terlipressin (Type: EXPERIMENTAL): None
- Normal Saline and norepinephrine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Positive and Quantitative Diagnosis of Pleural Effusions by Thoracic Ultrasonography in Patients With Acute Respiratory Failure in the Emergency Department

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient admitted to the ED~* AND Age \>= 18 years~* AND affiliated or beneficiary to a social security scheme~* AND with clinical signs of ARF:~  * Cyanosis, mottling, encephalopathy~ * Respiratory exhaustion (thoraco abdominal balancing, accessory muscle play)~ * Pulse oxygen saturation (SpO2) \<92% in the air~* AND/OR showing biological signs of ARF:~  * Arterial oxygen pressure (PaO2) \<60 mmHg~ * Or PaO2 / fraction of inspired oxygen (FiO2) ratio \<400.~Exclusion Criteria:~* Patient moribund or for whom a limitation of the care is envisaged~* Pregnant woman~* Absence of exploitable ultrasound image for any reason.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ultrasonography thoracic (Type: None): Ultrasonography thoracic

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Creon in HIV Patients With Steatorrhea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria HIV positive patients with clinically stable disease (Karnofsky Performance Status \> 40);~* Steatocrit \> 2 %;~* Females of child-bearing potential must have a negative pregnancy test during prestudy or the subject must be surgically sterile or be at least 1 year postmenopausal as judged by the investigator;~* Women of child-bearing potential must be using a medically acceptable method of birth control throughout the study~Exclusion Criteria~* Known allergy to pancreatin or any history of abnormal drug reaction;~* Known diagnosis of pancreatic exocrine insufficiency due to e.g. chronic pancreatitis or cystic fibrosis or pancreatectomy;~* Intake of an experimental drug within four weeks prior to entry into the study;~* Alcohol abuse within the last six months;~* Suspected non-compliance or non-cooperation;~* Any other lack of fitness, in the investigator's opinion, to participate in or to complete the study;~* Patients with a stool fat excretion \<= 7 g/day according to van de Kamer during the run-in period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Management of Hypotension In the Preterm Infant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Gestational age at birth less than 28 completed weeks, i.e. up to and including 27 weeks and 6 days.~2. Within 72 hours of birth~3. An indwelling arterial line, either umbilical or peripheral (e.g. radial, posterior tibial), suitably calibrated and zeroed, to monitor BP with the measuring dome at the level of the infant's mid-axillary line when supine~4. A pre-trial cerebral ultrasound scan demonstrating no evidence of grade 3 or 4 haemorrhage intraventricular haemorrhage (IVH)(i.e. intraparenchymal echodensity or echolucency, with or without acquired cerebral ventriculomegaly)~5. A mean blood pressure 1 mmHg or more below a mean BP value equivalent to the gestational age in completed weeks, which persists over a 15 minute period (mean BP \< gestational age)~Exclusion Criteria:~1. Considered non-viable by attending clinicians.~2. Life-threatening congenital abnormalities including congenital heart disease (excluding patent ductus arteriosus, small atrial and/or ventricular septal defect). Infants known to require surgical treatment e.g. congenital diaphragmatic hernia, trache-oesophageal fistula, omphalocele, gastroschisis. Neuromuscular disorders. Frank hypovolaemia. Hydrops Fetalis.~3. Cranial ultrasound abnormality grade 3 IVH or more prior to enrolment

- Gender: ALL
- Minimum Age: 23 Weeks
- Maximum Age: 27 Weeks
- Healthy Volunteers: f

Study Arms:
- dextrose 5% (Type: PLACEBO_COMPARATOR): IV Infusion
- Dopamine Hydrochloride (Type: EXPERIMENTAL): IV Infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues